[1] Goldstraw P, Chansky K, Crowley J, et al.The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. Journal of Thoracic Oncology, 2016, 11(1): 39-51.
[2] Pignon JP, Tribodet H, Scagliotti GV, et al.Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group[J]. Journal of Clinical Oncology, 2008, 26(21): 3552-3559.
[3] Muthusamy B, Patil PD, Pennell NA.Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer[J]. Journal of the National Comprehensive Cancer Network, 2022, 20(8): 953-961.
[4] Eichhorn F, Klotz LV, Bischoff H, et al.Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial[J]. BMC Cancer, 2019, 19(1): 413.
[5] Pataer A, Kalhor N, Correa AM, et al.Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy[J]. Journal of Thoracic Oncology, 2012, 7(5): 825-832.
[6] Hellmann MD, Chaft JE, William WN, et al.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. The Lancet Oncology, 2014, 15(1): e42-e50.
[7] Chaft JE, Oezkan F, Kris MG, et al.Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial[J]. Nature Medicine, 2022, 28(10): 2155-2161.
[8] Shu CA, Gainor JF, Awad MM, et al.Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial[J]. The Lancet Oncology, 2020, 21(6): 786-795.
[9] Forde PM, Chaft JE, Smith KN, et al.Neoadjuvant PD-1 Blockade in Resectable Lung Cancer[J]. New England Journal of Medicine, 2018, 378(21): 1976-1986.
[10] Provencio M, Nadal E, Insa A, et al.Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial[J]. The Lancet Oncology, 2020, 21(11): 1413-1422.
[11] Provencio M, Serna-Blasco R, Nadal E, et al.Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)[J]. Journal of Clinical Oncology, 2022, 40(25): 2924-2933.
[12] Forde PM, Spicer J, Lu S, et al.Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer[J]. New England Journal of Medicine, 2022, 386(21): 1973-1985.
[13] Hellmann MD, Paz-Ares L, Bernabe Caro R, et al.Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer[J]. New England Journal of Medicine, 2019, 381(21): 2020-2031.
[14] Cascone T, William WN, Weissferdt A, et al.Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial[J]. Nature Medicine, 2021, 27(3): 504-514.
[15] Wislez M, Mazieres J, Lavole A, et al.Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)[J]. Journal for Immuno Therapy of Cancer, 2022, 10(10): e005636.
[16] Rothschild SI, Zippelius A, Eboulet EI, et al.SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial[J]. Journal of Clinical Oncology, 2021, 39(26): 2872-2880.
[17] Arriagada R, Bergman B, Dunant A, et al.Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer[J]. New England Journal of Medicine, 2004, 350(4): 351-360.
[18] Felip E, Altorki N, Zhou C, et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. The Lancet, 2021, 398(10308): 1344-1357.
[19] Reck M, Mok TSK, Nishio M, et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. The Lancet Respiratory Medicine, 2019, 7(5): 387-401.
[20] Shibaki R, Akamatsu H, Kato T, et al.A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)[J]. Therapeutic Advances in Medical Oncology, 2021, 13: 175883592098764.
[21] Hui R, Garon EB, Goldman JW, et al.Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial[J]. Annals of Oncology, 2017, 28(4): 874-881.
[22] Ettinger DS, Wood DE, Aisner DL, et al.Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. Journal of the National Comprehensive Cancer Network, 2022, 20(5): 497-530.
[23] O'brien M, Paz-Ares L, Marreaud S, et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/ KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial[J]. The Lancet Oncology, 2022, 23(10): 1274-1286.
[24] National Cancer Institute (NCI). Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial[DB/OL].U.S. National Library of Medicine. https://clinicaltrials. gov/ct2/show/NCT04267848.
[25] Heymach JV, Mitsudomi T, Harpole D, et al.Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial[J]. Clinical Lung Cancer, 2022, 23(3): e247-e251.
[26] Canadian Cancer Trials Group. Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC[DB/OL].U.S. National Library of Medicine. https:// clinicaltrials.gov/ct2/show/NCT02273375. |
